Clinical trial / 2022
Oral administration of 250 mg/day of nicotinamide mononucleotide for 12 weeks was safe and significantly increased whole blood NAD+ levels in healthy subjects.
In a randomized, double-blind trial, 30 healthy volunteers received either 250 mg/day of NMN (n = 15) or a placebo (n = 15) for 12 weeks. Oral NMN caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed. Whole blood NAD+ and nicotinic acid mononucleotide (NAMN) levels were significantly increased after NMN administration, while NMN levels themselves were not. Additionally, the increase in NAD+ was strongly correlated with pulse rate prior to NMN administration.
- Study type
- Placebo-controlled, randomized, double-blind, parallel-group trial
- Who was studied
- 30 healthy subjects (15 receiving NMN, 15 receiving placebo)
- What was measured
- Safety (physiological and laboratory tests, adverse effects) and whole blood NAD+ and related metabolite levels
THE PAPER
Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.
Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T. Front Nutr, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.